- Language: English
- 42 Pages
- Published: February 2013
- Region: Global
Human Insulin Market in China 2011-2015
- Published: August 2012
- Region: China
- 39 pages
- Infiniti Research Limited
TechNavio's analysts forecast the Human Insulin market in China to grow at a CAGR of 19.2 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant increase in the diabetic population in China. The Human Insulin market in China has also been witnessing increased number of corporate agreements. However, the high cost of human insulin could pose a challenge to the growth of this market.
TechNavio's report, the Human Insulin Market in China 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on China; it also covers the Human Insulin market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Eli Lilly and Co., Novo Nordisk A/S, Sanofi SA, and Tonghua Dongbao Pharmaceutical Co. Ltd. The report also includes other vendors such as Abbott Laboratories Inc., Bayer Healthcare AG, Wockhardt Ltd., Piramal Healthcare Ltd., Glenmark Pharmaceuticals Ltd., SciGen Ltd., Gan & Lee Pharmaceutical Ltd., Wangbang Pharma Group Corp., Pfizer Inc., and Zhuhai United Laboratories Inc.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.
TechNavio Announces the Publication of its Report - Human Insulin Market in China 2011-2015
TechNavio today launched its report Human Insulin Market in China 2011-2015 based on an in-depth study focusing exclusively on China. The report aims to aid decision makers' understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio's Healthcare team said; ''The Human Insulin market in China has recently been witnessing a significant increase in the number of corporate agreements between global and regional vendors, which increases the competition in the market. In addition to the corporate agreements, the Human Insulin market in China is experiencing significant focus on innovation and product development.''
According to the report, one of the major growth factors driving the Human Insulin market in China is the significant increase in the number of patients suffering from diabetes and diabetes-related diseases in the country.
Further, the report also discusses that one of the major challenges is the high cost of the human insulin that is provided mainly by the leading vendors in China.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players. SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
04.1 Insulin Market in China
04.2 Human Insulin Market in China
Five Forces Analysis
05. Rate of Incidence and Prevalence
06. Vendor Landscape
07. Buying Criteria
08. Market Growth Drivers
09. Drivers and their Impact
10. Market Challenges
11. Impact of Drivers and Challenges
12. Market Trends
13. Key Vendor Analysis
13.1 Novo Nordisk A/S
13.2 Sanofi SA
13.3 Eli Lilly and Co.
13.4 Tonghua Dongbao Pharmaceutical Co. Ltd.
14. Other Reports in this Series
List of Exhibits:
Exhibit 1: Insulin Market in China 2011-2015 (US$ million)
Exhibit 2: Insulin Market in China by Product Segmentation
Exhibit 3: Insulin Market in China by Category Segmentation 2011
Exhibit 4: Insulin Market in China 2011-2015 by Revenue Segmentation (US$ million)
Exhibit 5: Insulin Market in China 2011-2015 by Segmentation (percentage)
Exhibit 6: Human Insulin Market in China 2011-2015 (US$ million)
Exhibit 7: Human Insulin Market in China by Vendor Segmentation 2011
Eli Lilly and Co., Novo Nordisk A/S, Sanofi SA, Tonghua Dongbao Pharmaceutical